Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Damages in patent reform

This article was originally published in The Gray Sheet

Executive Summary

Legislative reforms addressing how damages are awarded in patent infringement litigation is unnecessary based on a review of jury verdicts in 93 court cases between 2005 and 2007, says the device industry-backed Innovation Alliance. The Feb. 13 1report argues that guidelines currently used to calculate damages work well, and judges effectively review verdicts for appropriateness. The device industry is opposed to a so-called "apportionment provision" that passed in House patent reform bill H.R. 1908 last fall, which it fears could limit damages unfairly. According to AdvaMed CEO Steve Ubl, the Senate's discussion on the apportionment provision in companion bill S. 1145 is fluid (2"The Gray Sheet" Feb. 4, 2008, p. 18). Reports are that the Senate is now unlikely to take up the bill before late March

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel